» Articles » PMID: 7500096

Clinical and [18F] Dopa PET Findings in Early Parkinson's Disease

Overview
Date 1995 Dec 1
PMID 7500096
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty seven patients with recent onset (mean symptom duration 22 (SD 14) months, Hoehn and Yahr score 1.8 (SD 0.7)) Parkinson's disease were studied with [18F]dopa PET. There was a correlation between putamen influx (Ki) and clinical rating, but not symptom duration. In 11 patients with hemi-Parkinson's disease of recent onset there were significant differences between normal (mean 0.0123 (SD 0.0023)), asymptomatic (mean 0.0099 (0.0020)) and symptomatic (mean 0.0070 (00.014)) putamen Kis. This suggests that Parkinson's disease has a widely variable rate of progression, and is most compatible with a short preclinical period. Symptom onset was estimated at a putamen Ki of between 57% and 80% of normal. Most ipsilateral putamen Ki values in early asymmetric Parkinson's disease fell within the normal range. The implication is that either the disease is not established in the ipsilateral putamen or that the technique is insufficiently sensitive to detect it. Discriminant analysis completely separated the normal and Parkinson's disease cohorts, but when a discriminant function from a previous study was used predictively four of the 27 patients with Parkinson's disease were incorrectly classified as normal.

Citing Articles

Cerebellar activity in hemi-parkinsonian rats during volitional gait and freezing.

DeAngelo V, Gehan A, Paliwal S, Ho K, Hilliard J, Chiang C Brain Commun. 2024; 6(5):fcae246.

PMID: 39464215 PMC: 11503953. DOI: 10.1093/braincomms/fcae246.


Effects of dopaminergic treatment on inhibitory control differ across Hoehn and Yahr stages of Parkinson's disease.

Mirabella G, Pilotto A, Rizzardi A, Montalti M, Olivola E, Zatti C Brain Commun. 2024; 6(1):fcad350.

PMID: 38162902 PMC: 10757450. DOI: 10.1093/braincomms/fcad350.


Daily Habits in Parkinson's Disease: Validation of the Daily Habit Scale.

Georgiev D, Torkmani A, Song R, Limousin P, Jahanshahi M Mov Disord Clin Pract. 2023; 10(10):1485-1495.

PMID: 37868920 PMC: 10585975. DOI: 10.1002/mdc3.13863.


Using F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.

Beauchamp L, Dore V, Villemagne V, Xu S, Finkelstein D, Barnham K Neurology. 2023; 101(22):e2314-e2324.

PMID: 37816639 PMC: 10727223. DOI: 10.1212/WNL.0000000000207748.


The Role of a Dopamine-Dependent Limbic-Motor Network in Sensory Motor Processing in Parkinson Disease.

Mann L, Servant M, Hay K, Song A, Trujillo P, Yan B J Cogn Neurosci. 2023; 35(11):1806-1822.

PMID: 37677065 PMC: 10594953. DOI: 10.1162/jocn_a_02048.


References
1.
Snow B, Tooyama I, McGeer E, Yamada T, Calne D, Takahashi H . Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993; 34(3):324-30. DOI: 10.1002/ana.410340304. View

2.
Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R . Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab. 1993; 13(5):881-8. DOI: 10.1038/jcbfm.1993.110. View

3.
Sawle G, Playford E, Burn D, Cunningham V, Brooks D . Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol. 1994; 51(3):237-43. DOI: 10.1001/archneur.1994.00540150027011. View

4.
Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I . Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med. 1994; 35(6):955-63. View

5.
Sawle G, Burn D, Morrish P, Lammertsma A, Snow B, Luthra S . The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology. 1994; 44(7):1292-7. DOI: 10.1212/wnl.44.7.1292. View